Star-Lld Well Tolerated With No Dose-Related Toxicity Or Adverse EventsStar Lld Achieved 90% Bioavailability Across All DosesPlasma Levels Showed A 90% Lower Cmax, A 70% Lower Auc, And Sustained Cmin At Targeted Dose LevelsStudy Validated Compatibility And Utility Of Ambulatory Pump Delivery System With Star-Lld Subcutaneous FormulationStarton Therapeutics Inc., A Clinical Stage Biotechnology Company Announced Today Positive Results From High-Level Data From Its Phase 1 Study Of Star-Lld, Evaluating The Pharmacokinetics (Pk) And Safety Of The Company
